Tesomet/Tesofensine
Hypothalamic Obesity, Prader-Willi Syndrome
Phase 2b/3Active (Status may be deprioritized)
Key Facts
Indication
Hypothalamic Obesity, Prader-Willi Syndrome
Phase
Phase 2b/3
Status
Active (Status may be deprioritized)
Company
About Saniona
Saniona is a Danish biotech pioneer with a core competency in ion channel modulation, a historically challenging drug target class. The company has built a robust discovery engine and a library of over 20,000 proprietary molecules, translating this platform into a clinical-stage pipeline focused on epilepsy and rare CNS disorders. A recent licensing agreement with Jazz Pharmaceuticals validates its approach and provides non-dilutive funding. The company's strategy is to advance its own programs while leveraging partnerships to maximize the value of its ion channel platform.
View full company profile